Glenmark Pharmaceuticals has announced a strategic transition to end-to-end direct commercialization and distribution for RYALTRIS in the United States, effective April 1, 2026. This move marks the company’s first innovative product rollout in the region, aiming to strengthen its U.S. presence through focused brand strategy, improved market access, and direct customer engagement to support healthcare providers and patients more effectively.
Expanding Innovative Presence
Glenmark Pharmaceuticals Inc., USA, is taking a significant step in its regional expansion by assuming full control over the commercialization and distribution of RYALTRIS (Olopatadine Hydrochloride and Mometasone Furoate) nasal spray. This transition represents a sustainable approach to building a more robust, direct commercial footprint within the competitive U.S. pharmaceutical market.
Product Overview and Market Impact
Launched in the U.S. in 2022, RYALTRIS is a fixed-dose combination nasal spray approved for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and pediatric patients 12 years and older. By integrating an antihistamine and a corticosteroid into a single formulation, the product addresses key patient needs regarding symptom control and treatment adherence.
Operational Strategy and Growth
By moving to an end-to-end model, Glenmark will directly manage brand strategy and market access, facilitating closer alignment with healthcare providers. According to Marc Kikuchi, President & Business Head, North America, this development allows for greater operational direction and is a vital step in strengthening the company’s innovative business segment in the U.S.
Global Reach
Beyond its U.S. operations, RYALTRIS continues to see widespread international success. Currently approved in major markets including the European Union, United Kingdom, Australia, South Korea, Russia, and China, the product has expanded its global presence to 55 countries, with 11 additional markets added during FY26 alone.
Source: BSE
